Limitations of Widely Used High-Risk Human Papillomavirus Laboratory-Developed Testing in Cervical Cancer Screening.
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.
Filed under: Drug and Alcohol Rehabilitation
Drug Healthc Patient Saf. 2012; 4: 167-72
Naryshkin S, Austin RM
To increase awareness of the limitations of high-risk human papillomavirus (hrHPV) laboratory-developed testing (LDT) widely used in US cervical cancer screening.A young woman in her 30s was diagnosed and treated for stage 1B1 cervical squamous cell carcinoma in which HPV 16 DNA was detected using polymerase chain reaction testing. Both 1 month before and 42 months before cervical cancer diagnosis, the patient had highly abnormal cytology findings; however, residual SurePath™ (Becton, Dickson and Company, Franklin Lakes, NJ) vial fluid yielded negative Hybrid Capture 2 (HC2; Qiagen NV, Hilden, Germany) hrHPV LDT results from each of the two specimens. This prompted questions to be asked concerning the performance characteristics of hrHPV LDT. A review of the available data indicates that (1) purification of DNA from SurePath specimens requires complex sample preparation due to formaldehyde crosslinking of proteins and nucleic acids, (2) HC2-SurePath hrHPV testing had not been Food and Drug Administration-approved after multiple premarket approval submissions, (3) detectible hrHPV DNA in the SurePath vial decreases over time, and (4) US laboratories performing HC2-SurePath hrHPV LDT testing are not using a standardized manufacturer-endorsed procedure.Recently updated cervical screening guidelines in the US recommend against the use of hrHPV LDT in cervical screening, including widely used HC2 testing from the SurePath vial. The manufacturer recently issued a technical bulletin specifically warning that use of SurePath samples with the HC2 hrHPV test may provide false negative results and potentially compromise patient safety. Co-collection using a Food and Drug Administration-approved hrHPV test medium is recommended for HPV testing of patients undergoing cervical screening using SurePath samples.
HubMed – drug
Dwight Muhammad Qawi vs. Matthew Saad Muhammad – 2 – Background Qawi, then known as Dwight Braxton, was born in Baltimore, Maryland, but grew up in Camden, New Jersey, where he got involved with crime at a young age. He was eventually convicted of armed robbery and spent around five years in prison.[2] It was at Rahway that Braxton found his place in life. The prison had an extensive boxing program and one of its inmates, James Scott, was a light heavyweight title contender who fought several times inside the prison itself. Braxton took up the sport, and when he was released from prison in 1978, immediately became a professional boxer. Qawi’s style was most often likened to Joe Frazier and with good reason as he had trained in Fraziers Philadelphia gym as a professional. [edit] Professional career He went 1-1-1 in his first three pro fights, but then reeled off 14 straight victories to move into the world rankings at light heavyweight. The last of those wins came on September 5, 1981, when Braxton returned to Rahway to fight Scott, with the winner promised a shot at Matthew Saad Muhammad’s WBC world championship belt. Braxton won a unanimous 10-round decision. On December 19 of the same year, Braxton faced Saad Muhammad in Atlantic City. The ex-convict was the underdog against Saad, one of the most popular fighters of his generation and a fellow Hall of Famer, but Braxton defeated him on a 10th-round technical knockout and became a world champion for the first time.[3] It was shortly after this that he announced his …
More Drug And Alcohol Rehabilitation Information…